Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).
Kiszala, the CEO and co-founder of intoDNA, to explore how a breakthrough in understanding DNA damage and repair could ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, ...
Dr. Roach weighs in on whether a patient should proceed with a prostate biopsy after conflicting test results.
A doctor advises a 68-year-old patient with a high 4Kscore result to proceed with a prostate biopsy despite a low-risk MRI.
I am 68 years old and have an enlarged prostate and benign prostatic hyperplasia (BPH). I’ve been taking tamsulosin for about ...
21h
Dear Doctor: My physician says my prostate cancer risk is nearly 50%, but a biopsy comes with risks
However, I think there are a number of other tests that could be done, such as a Prostate Health Index (phi) test or perhaps others. Would I benefit from taking a different test, or should we stick ...
21h
Dear Doctor: There's a 49% chance of aggressive prostate cancer, but my doctor is hesitant to biopsy
A conflicting MRI result and the complications of blood thinner use have left one 68-year-old man and his physician at a crossroads.
A physician advises a 68-year-old patient with a high 4Kscore result to consider a prostate biopsy despite being on warfarin, ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral ...
Research reinforces the significance of genomic and epigenomic profiling approaches to characterize tumor types, identify biomarkers, and support risk stratification Presentations reflect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results